Patents by Inventor Takashi Kadowaki
Takashi Kadowaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100303855Abstract: A substance preventing adverse actions of conventional fibrate-series drugs as therapeutic agents for the metabolic syndrome and dyslipidemia to enhance the therapeutic effects thereof comprises an extract from Dunaliella salina or Dunaliella bardawil, for administration in combination with the fibrate-series drugs. The substance suppresses liver hypertrophy caused by the fibrate-series drugs as PPAR-? agonists and has an action of promoting fat combustion, suppressing fat synthesis and suppressing cell proliferation, to prevent disorders of liver functions.Type: ApplicationFiled: August 9, 2010Publication date: December 2, 2010Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Nobuo Mori, Osamu Sueno, Sachiko Kawamoto
-
Publication number: 20100273708Abstract: The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position ?188 to position ?157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity. Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases.Type: ApplicationFiled: April 19, 2010Publication date: October 28, 2010Applicants: TOUDAI TLO, Ltd., NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Takashi KADOWAKI, Toshimasa Yamauchi, Shoko Kitajima, Yusuke Ito
-
Patent number: 7781171Abstract: The invention provides a method of pretreating a sample for conveniently, quickly and accurately measuring the total amount of adiponectin present in a biological sample contaminated with various adiponectin multimers. The method of measuring an sample for immunologically assaying the total amount of adiponectin present in the sample comprises reacting, with an adiponectin-containing sample, at least one of a reducing agent, an acid or a salt thereof, a surfactant, and a protease.Type: GrantFiled: October 15, 2004Date of Patent: August 24, 2010Assignees: Daiichi Pure Chemicals Co., Ltd., Toudai TLO, Ltd.Inventors: Hiroyuki Ebinuma, Hirokazu Yago, Yuka Akimoto, Osamu Miyazaki, Takashi Kadowaki, Toshimasa Yamauchi
-
Patent number: 7741080Abstract: The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position ?188 to position ?157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity. Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases.Type: GrantFiled: March 31, 2005Date of Patent: June 22, 2010Assignees: Nissan Chemical Industries, Ltd., Toudai TLO, LtdInventors: Takashi Kadowaki, Toshimasa Yamauchi, Shoko Kitajima, Yusuke Ito
-
Publication number: 20100120674Abstract: The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improving insulin resistance and treating type 2 diabetes by administering the aforementioned agent(s).Type: ApplicationFiled: March 3, 2008Publication date: May 13, 2010Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: TAKASHI KADOWAKI, TOSHIMASA YAMAUCHI, JUNJI KAMON, HIRONORI WAKI, RYOZO NAGAI, SATOSHI KIMURA, MOTOO TOMITA
-
Publication number: 20100098720Abstract: A substance preventing adverse actions of conventional fibrate-series drugs as therapeutic agents for the metabolic syndrome and dyslipidemia to enhance the therapeutic effects thereof comprises an extract from Dunaliella salina or Dunaliella bardawil, for administration in combination with the fibrate-series drugs. The substance suppresses liver hypertrophy caused by the fibrate-series drugs as PPAR-? agonists and has an action of promoting fat combustion, suppressing fat synthesis and suppressing cell proliferation, to prevent disorders of liver functions.Type: ApplicationFiled: April 24, 2009Publication date: April 22, 2010Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Nobuo Mori, Osamu Sueno, Sachiko Kawamoto
-
Publication number: 20100062541Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: ApplicationFiled: January 29, 2009Publication date: March 11, 2010Applicants: TOUDAI TLO, Ltd., Nissan Chemical Industries, Ltd.Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon
-
Publication number: 20090291461Abstract: Kits and methods for selectively assaying a target adiponectin multimer in a biological sample. Such methods accurately evaluate the relationship between a disease and adiponectin through selective assay of adiponectin multimers and provide information that cannot be obtained through measurement of the total amount of adiponectin alone. A method for selectively assaying a target adiponectin multimer in a biological sample comprising distinguishing target adiponectin multimer from the other adiponectin multimers by using a protease and/or an antibody.Type: ApplicationFiled: May 19, 2009Publication date: November 26, 2009Applicants: DAIICHI PURE CHEMICALS CO., LTD, TOUDAI TLO, LTD.Inventors: Hiroyuki EBINUMA, Hirokazu Yago, Yuka Akimoto, Osamu Miyazaki, Takashi Kadowaki, Toshimasa Yamauchi, Kazuo Hara
-
Patent number: 7608405Abstract: Methods for selectively assaying a target adiponectin multimer in a biological sample. Such methods accurately evaluate the relationship between a disease and adiponectin through selective assay of adiponectin multimers and provide information that cannot be obtained through measurement of the total amount of adiponectin alone. A method for selectively assaying of a target adiponectin multimer in a biological sample comprising distinguishing target adiponectin multimer from the other adiponectin multimers by using a protease and/or an antibody.Type: GrantFiled: October 15, 2004Date of Patent: October 27, 2009Assignees: Daiichi Pure Chemicals Co., Ltd., Toudai TLO, Ltd.Inventors: Hiroyuki Ebinuma, Hirokazu Yago, Yuka Akimoto, Osamu Miyazaki, Takashi Kadowaki, Toshimasa Yamauchi, Kazuo Hara
-
Publication number: 20090239938Abstract: A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.Type: ApplicationFiled: July 15, 2008Publication date: September 24, 2009Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Takashi KADOWAKI, Toshimasa YAMAUCHI, Naoto KUBOTA, Yasuo TERAUCHI, Tetsuya KUBOTA, Tetsuo NODA, Ryozo NAGAI, Yasushi IMAI
-
Patent number: 7523798Abstract: The duct comprises the upper member and the lower member, which are formed separately and assembled integrally by being attached to one another. There is provided the seal member to interconnect the opening at the lower member and the intercooler, which is pressed against the upper face of the intercooler. The front side of the lower member is supported at the shroud panel, and the rear side of the upper panel is supported at the cowl panel. Thus, the rear attachment portion is detached earlier than the front attachment portion at the pedestrian's hit. Accordingly, the duct can be split surely and the engine hood can be allowed to be properly deformed without being prevented, so that the protection of the head of pedestrians can be attained properly.Type: GrantFiled: August 3, 2005Date of Patent: April 28, 2009Assignee: Mazda Motor CorporationInventors: Takaaki Muramatsu, Takashi Kadowaki, Noriaki Fujita
-
Patent number: 7501490Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: GrantFiled: November 13, 2006Date of Patent: March 10, 2009Assignees: Toudai TLO, Ltd., Nissan Chemical Industries, Ltd.Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon
-
Patent number: 7419955Abstract: A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.Type: GrantFiled: May 26, 2003Date of Patent: September 2, 2008Assignee: Japan Science and Technology AgencyInventors: Takashi Kadowaki, Toshimasa Yamauchi, Naoto Kubota, Yasuo Terauchi, Tetsuya Kubota, Tetsuo Noda, Ryozo Nagai, Yasushi Imai
-
Publication number: 20070238649Abstract: The present inventors revealed by using fasted and refed mice, that AdipoR1/R2 is a regulator of metabolic sensitivity to nutritional conditions and insulin. They showed that mRNA level of AdipoR1/R2 increased by STZ treatment, and that this increase was restored by insulin. The present inventors confirmed in vitro that insulin reduces AdipoR1/R2 mRNAs in myocytes and such. It was also confirmed that in insulin-resistant models, the AdipoR1/R2 expression was downregulated, and that AMP kinase activation by adiponectin was decreased. The present inventors discovered by using insulin signaling pathway inhibitors, that the downregulation of adiponectin receptors by insulin was mediated by the PI3-kinase/Foxo1 pathway.Type: ApplicationFiled: March 4, 2005Publication date: October 11, 2007Inventors: Takashi Kadowaki, Toshimasa Yamauchi
-
Publication number: 20070203061Abstract: The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position ?188 to position ?157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity. Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases.Type: ApplicationFiled: March 31, 2005Publication date: August 30, 2007Applicants: TOUDAI TLO, LTD, NISSAN CHEMICAL INDUSTRIES, LTDInventors: Takashi Kadowaki, Toshimasa Yamauchi, Shoko Kitajima, Yusuke Ito
-
Publication number: 20070065891Abstract: The invention provides a method of pretreating a sample for conveniently, quickly and accurately measuring the total amount of adiponectin present in a biological sample contaminated with various adiponectin multimers. The method of measuring an sample for immunologically assaying the total amount of adiponectin present in the sample comprises reacting, with an adiponectin-containing sample, at least one of a reducing agent, an acid or a salt thereof, a surfactant, and a protease.Type: ApplicationFiled: October 15, 2004Publication date: March 22, 2007Applicants: DAIICHI PURE CHEMICALS CO., LTD., TOUDAI TLO, LTD.Inventors: Hiroyuki Ebinuma, Hirokazu Yago, Yuka Akimoto, Osamu Miyazaki, Takashi Kadowaki, Toshimasa Yamauchi
-
Publication number: 20070054314Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: ApplicationFiled: November 13, 2006Publication date: March 8, 2007Applicants: Center for Advanced Science and Technology Incubation, Ltd., Nissan Chemical Industries, Ltd.Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon
-
Publication number: 20070042424Abstract: We have discovered a “human adiponectin ELISA kit”, which can specifically measure adiponectin in human blood serum (or blood plasma) or in extracted fluid from lipocytes or culture supernatant fluid. After fractioning human serum by use of gel filtration column, each fraction was measured by the present kit, and as a result, adiponectin immunity activity was detected as a plurality of peaks at above 670 kD of molecular weight. From the results, it is presumed that adiponectin is present in the blood as a polymer or forms a complex with polymer proteins.Type: ApplicationFiled: October 15, 2004Publication date: February 22, 2007Applicants: DAIICHI PURE CHEMICALS CO., LTD., TOUDAI TLO, LTD.Inventors: Hiroyuki Ebinuma, Hirokazu Yago, Yuka Akimoto, Osamu Miyazaki, Takashi Kadowaki, Toshimasa Yamauchi, Kazuo Hara
-
Publication number: 20060208841Abstract: An actuating mechanism for a switching device includes a plurality of electromagnets used in combination. Each electromagnet includes a coil, a movable iron core adapted to move on the center axis of the coil, and a stationary iron core provided so as to cover the upper and lower surfaces and the outer peripheral surface of the coil. A permanent magnet is arranged in a gap surrounded by the movable iron core and the stationary core.Type: ApplicationFiled: May 19, 2006Publication date: September 21, 2006Inventors: Ayumu Morita, Yasuaki Suzuki, Masato Yabu, Tooru Tanimizu, Yozo Shibata, Takashi Kadowaki
-
Publication number: 20060199761Abstract: The invention provides an insulin resistance improving agent which contains, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a therapeutic agent for type 2 diabetes, which contains, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention reverses insulin resistance induced from a high fat diet and associated with obesity, and therefore, enables treatment of type 2 diabetes, which is the most common among other types of diabetes.Type: ApplicationFiled: July 26, 2002Publication date: September 7, 2006Applicant: Japan Science And Technology AgencyInventors: Takashi Kadowaki, Toshimasa Yamauchi, Junji Kamon, Hironori Waki, Ryozo Nagai, Satoshi Kimura, Motto Tomita